nach oben

Reactions Weekly

Erschienen in:

01.08.2019 | Case report

Axicabtagene ciloleucel

Neurotoxicity, with both diffuse encephalopathy and focal neurological features: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective analysis of 6 patients, who received axicabtagene ciloleucel between February 2018 and April 2018 at Memorial Sloan Kettering Cancer Center (MSKCC), two patients [ages and sexes not stated] were described, who developed neurotoxicity characterised by both diffuse encephalopathy and focal neurological features following treatment with axicabtagene ciloleucel for refractory large B-cell lymphoma [dosages, routes, durations of treatments to reaction onsets not stated]. …

Sequeira A, et al. Clinical neurological features and electrographic patterns of patients with relapsed or refractory large b-cell lymphoma treated with axicabtagene ciloleucel at memorial sloan kettering cancer center (MSKCC). Neuro-Oncology 20 (Suppl. 6): vi194-vi195, Nov 2018. Available from: URL: http://doi.org/10.1093/neuonc/noy148 [abstract] - USA

Titel: Axicabtagene ciloleucel
Neurotoxicity, with both diffuse encephalopathy and focal neurological features: 2 case reports
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65822-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Axicabtagene ciloleucel

Neurotoxicity, with both diffuse encephalopathy and focal neurological features: 2 case reports

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Apremilast

Cotrimoxazole/dapsone/pyrimethamine

Telbivudine

Heparin

Fluconazole

Immunosuppressants